EOFY Sale now active - 20% off Storewide! Free shipping on all orders $100+ | Australia Wide
EOFY Sale now active - 20% off Storewide! Free shipping on all orders $100+ | Australia Wide
CJC-1295 Peptide Research Australia | Growth Hormone Peptide Guide
| Sequence length | 29 amino acids (modified GHRH fragment) |
|---|---|
| Receptor target | GHRH receptor |
| Version supplied | No DAC (shorter half-life, hours) |
| Common research pairing | Ipamorelin (GHS-R, parallel pathway) |
| Research maturity | Well-characterised receptor mechanism; limited human outcome data |
CJC-1295 vs Ipamorelin
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Receptor target | GHRH receptor | GHS-R (ghrelin receptor) |
| Sequence length | 29 amino acids | 5 amino acids |
| Pathway position | Parallel upstream pathway | Parallel upstream pathway |
| Half-life (No DAC) | Hours | Short, research-grade |
| Commonly combined with | Ipamorelin | CJC-1295, Tesamorelin |
CJC-1295 Australia research centres on a GHRH (growth hormone releasing hormone) receptor agonist — a modified fragment engineered for substantially greater stability than native GHRH. CJC-1295 is one of the most studied upstream GH-axis peptides, and is most commonly researched alongside Ipamorelin to study combined receptor stimulation. This guide covers CJC-1295's mechanism, the distinction between CJC-1295 and CJC-1295 with DAC, how it compares to Ipamorelin, and the practical handling steps for research.
Key Research Points at a Glance
- A modified GHRH receptor agonist engineered for substantially improved stability over native GHRH
- 29-amino-acid fragment, structurally distinct from the 5-amino-acid GHS-R agonist Ipamorelin
- Acts on the GHRH receptor — a separate upstream pathway from GHS-R agonists
- "No DAC" version has a shorter research half-life than the DAC-modified version, a key research design variable
- Frequently co-researched with Ipamorelin to study combined upstream GH-axis stimulation
- Predominantly pre-clinical and early-phase research base
What Is CJC-1295? Origin and Structure
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH), modified specifically to resist the rapid enzymatic degradation that limits native GHRH's research utility. The modification targets specific amino acid positions vulnerable to enzymatic cleavage, extending the compound's stability without changing its fundamental receptor-binding mechanism.
Two distinct versions exist in research contexts: CJC-1295 without DAC (Drug Affinity Complex) and CJC-1295 with DAC. The DAC modification further extends stability via albumin binding, producing a substantially longer research half-life. PhaseOne supplies the No DAC version, which is more commonly used in combination research protocols specifically because its shorter half-life allows more precise control over dosing timing.
CJC-1295 stability modification diagram
Minimalist scientific diagram showing native GHRH on the left being rapidly broken down by enzymes, compared to modified CJC-1295 on the right resisting degradation for longer. Clean line-art, blue/white palette, no photorealistic elements.
Mechanism of Action
CJC-1295's research interest centres on GHRH receptor agonism — stimulating the same upstream receptor that native GHRH activates, but with a substantially longer window of activity due to its enzymatic-resistance modification.
GHRH Receptor Agonism
By activating the GHRH receptor, CJC-1295 is proposed to stimulate the pituitary's growth hormone release pathway — the same upstream signal native GHRH provides, but sustained for longer due to the stability modification. This is mechanistically distinct from GHS-R agonists like Ipamorelin, which act on an entirely separate receptor.
GHRH receptor pathway diagram
Minimalist infographic showing CJC-1295 binding the GHRH receptor with an arrow to the pituitary gland, labelled simply. Clean line-art, blue/white palette, no photorealistic elements.
No DAC vs DAC: A Key Research Design Variable
The presence or absence of the DAC modification fundamentally changes CJC-1295's research half-life and is one of the most important variables to understand before designing a study around this compound. No DAC CJC-1295 has a research half-life measured in hours, making it more suitable for protocols requiring precise timing control or combination dosing with GHS-R agonists. DAC-modified CJC-1295 extends to a half-life measured in days via albumin binding, which suits different research designs entirely.
Why CJC-1295 Is Studied With Ipamorelin
Because CJC-1295 and Ipamorelin act on separate receptors — GHRH receptor and GHS-R respectively — combining them allows researchers to study combined upstream GH-axis stimulation rather than a single pathway in isolation. See our Ipamorelin guide for that compound's selectivity profile and mechanism.
CJC-1295 + Ipamorelin combined pathway diagram
Minimalist infographic showing two separate upstream pathways converging on growth hormone release: left labelled GHRH receptor (CJC-1295), right labelled GHS-R (Ipamorelin). Clean line-art, blue/white palette, no photorealistic elements.
Sequence Length Compared to Tesamorelin
CJC-1295's 29-amino-acid fragment is shorter than Tesamorelin's 44-amino-acid sequence, despite both acting on the GHRH receptor. Tesamorelin's longer sequence is closer to the structure of native GHRH, which is part of why the two compounds are sometimes studied comparatively within the same receptor pathway — see our growth hormone peptide guide for that comparison.
Animal-Model and Early Research Context
CJC-1295's research base includes animal-model studies on sustained GHRH receptor activation and some early-phase human research examining growth hormone and IGF-1 response curves following dosing. As with most GH-axis peptides, the bulk of detailed mechanistic characterisation comes from pre-clinical work, with human outcome data comparatively limited for general research purposes.
GH and IGF-1 response curve chart
Simple line-chart mockup showing growth hormone and IGF-1 levels rising and falling over time following dosing, two coloured lines, clean minimalist scientific chart style, white background, no photorealistic elements.
What the Current Research Does Not Establish
Despite a well-characterised receptor mechanism, long-term human outcome data for CJC-1295 research remains limited, and the difference between No DAC and DAC versions is frequently conflated in informal research discussion — claims should specify which version a given finding applies to, since their pharmacokinetic profiles differ substantially.
Reconstitution, Storage and Handling
CJC-1295 ships as a lyophilised powder. Reconstitution requires bacteriostatic water — see our reconstitution guide and dosage calculator for the process and concentration calculations.
Once reconstituted, refrigerate immediately — see our storage guide for the full set of stability variables.
Verifying CJC-1295 Purity
Every PhaseOne CJC-1295 batch is independently tested via HPLC and ships with a batch-specific Certificate of Analysis. See our HPLC testing guide and research standards guide for the full process.
HPLC chromatogram example
Simplified line-chart mockup of an HPLC chromatogram: a single sharp peak on an x/y axis labelled 'retention time' and 'absorbance', clean minimalist scientific chart style, blue line on white background, no photorealistic elements.
Common Misconceptions in CJC-1295 Research Discussion
The most common misconception is treating No DAC and DAC CJC-1295 as interchangeable — their half-lives differ by an order of magnitude, which fundamentally changes appropriate research design. A second misconception is assuming GHRH receptor agonism and GHS-R agonism are redundant; they're separate upstream pathways studied together precisely because they're not.
Related Research Guides
For the broader GH-axis category, see our growth hormone peptide guide . For the common research pairing, see our Ipamorelin guide . For handling, see our reconstitution guide and storage guide .
Sourcing CJC-1295 for Research in Australia
Researchers sourcing CJC-1295 in Australia should prioritise suppliers who provide independent, batch-specific HPLC verification and are explicit about which version (No DAC vs DAC) is supplied. PhaseOne supplies CJC-1295 No DAC alongside the full GH-axis research category — Ipamorelin, Tesamorelin, HGH 191AA and IGF-1 LR3 — with the same third-party testing standard applied across every product, shipped Australia-wide.
Frequently Asked Questions
What's the difference between CJC-1295 and CJC-1295 with DAC?
No DAC has a research half-life of hours; the DAC-modified version extends to days via albumin binding. PhaseOne supplies the No DAC version, more commonly used in combination research where precise dosing timing matters.
Why is CJC-1295 studied with Ipamorelin?
Because they act on separate receptors (GHRH receptor vs GHS-R), combining them lets researchers study combined upstream GH-axis stimulation rather than a single pathway in isolation.
How does CJC-1295 differ from Tesamorelin?
Both act on the GHRH receptor, but CJC-1295 is a 29-amino-acid fragment while Tesamorelin is a longer 44-amino-acid sequence closer to native GHRH.
How should CJC-1295 be reconstituted?
Using bacteriostatic water, following the same general process as other lyophilised research peptides — slow injection, gentle swirling, and immediate refrigeration once dissolved.
How is CJC-1295 purity verified?
PhaseOne verifies every CJC-1295 batch via independent third-party HPLC testing with a batch-specific Certificate of Analysis.
Is CJC-1295's mechanism well understood?
Its GHRH receptor binding and stability modification are well characterised, though long-term human outcome data for general research applications remains comparatively limited.
Disclaimer
All products supplied by PhaseOne are intended strictly for laboratory research purposes only. Products are not intended for human consumption, therapeutic use, cosmetic use, veterinary use, or diagnostic applications.
